Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

By CNBC · CNBC

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.